Pipeline

Primary programs

From the beginning, we recognized that with the breadth of therapeutic possibilities in condensate biology, exploring diseases on our own and with experienced partners would accelerate our growth and prove the value of this revolutionary approach.
Four years since our founding, we are partnering with the world’s leading pharma companies to explore modulating condensates to target diseases across many therapeutic areas, while growing an ambitious pipeline of our own discovery programs.
ONCOLOGY
Ovarian cancer
Colorectal cancer
Neurology
DM1
ALS / FTD
Rett syndrome
Virology
HIV
Cardiopulmonary
Cardiology
Pulmonology
Nephrology
Metabolic
Insulin resistance
DM1 = Myotonic Dystrophy Type 1, ALS = Amyotrophic Lateral Sclerosis, FTD = FrontoTemporal Dementia, HIV = Human Immunodeficiency Virus

Partnerships

Multi-year, multi-program research collaboration, option and license agreement addressing broad therapeutic area of cardiovascular diseases.  The partnership will leverage Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule compound library and R&D capabilities to  identify and advance novel therapeutics.

Exclusive research collaboration to utilize Dewpoint’s proprietary platform for condensate biology to discover and develop therapies with a novel mechanism for the treatment of HIV.

Research collaboration that leverages Dewpoint’s technology platform to generate a condensate relevant, HTS amenable assay to screen Pfizer’s proprietary compound collection to identify compounds for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy.

Research and development partnership to identify drug candidates using Dewpoint’s discovery platform related to biomolecular condensates to treat insulin resistance. The partnership brings together Novo Nordisk’s global leadership in treating diabetes and metabolic diseases with Dewpoint’s groundbreaking discovery and AI technology platform to identify modulators of biomolecular condensates.

Dewpoint Therapeutics
451 D Street, Suite 104
Boston, MA 02210
USA
© 2019-2023 - Dewpoint Therapeutics

Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science